- Home
- CYH vs CGEM Comparison
CYH vs CGEM Comparison
Compare CYH & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYH
- CGEM
- Stock Information
- Founded
- CYH 1985
- CGEM 2016
- Country
- CYH United States
- CGEM United States
- Employees
- CYH N/A
- CGEM N/A
- Industry
- CYH Hospital/Nursing Management
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- CYH Health Care
- CGEM Health Care
- Exchange
- CYH Nasdaq
- CGEM Nasdaq
- Market Cap
- CYH 482.7M
- CGEM 530.0M
- IPO Year
- CYH 1991
- CGEM 2021
- Fundamental
- Price
- CYH $3.32
- CGEM $7.67
- Analyst Decision
- CYH Hold
- CGEM Strong Buy
- Analyst Count
- CYH 8
- CGEM 5
- Target Price
- CYH $4.27
- CGEM $30.00
- AVG Volume (30 Days)
- CYH 2.2M
- CGEM 348.1K
- Earning Date
- CYH 07-23-2025
- CGEM 08-07-2025
- Dividend Yield
- CYH N/A
- CGEM N/A
- EPS Growth
- CYH N/A
- CGEM N/A
- EPS
- CYH N/A
- CGEM N/A
- Revenue
- CYH $12,653,000,000.00
- CGEM N/A
- Revenue This Year
- CYH N/A
- CGEM N/A
- Revenue Next Year
- CYH $3.49
- CGEM N/A
- P/E Ratio
- CYH N/A
- CGEM N/A
- Revenue Growth
- CYH 1.05
- CGEM N/A
- 52 Week Low
- CYH $2.24
- CGEM $6.85
- 52 Week High
- CYH $6.29
- CGEM $21.01
- Technical
- Relative Strength Index (RSI)
- CYH 44.49
- CGEM 38.41
- Support Level
- CYH $3.01
- CGEM $8.47
- Resistance Level
- CYH $3.27
- CGEM $9.25
- Average True Range (ATR)
- CYH 0.19
- CGEM 0.45
- MACD
- CYH -0.07
- CGEM -0.12
- Stochastic Oscillator
- CYH 31.12
- CGEM 5.06
About CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.